tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Orchitis D009920 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Opportunistic Infections D009894 8 associated lipids
Oliguria D009846 2 associated lipids
Obesity D009765 29 associated lipids
Nocardia Infections D009617 6 associated lipids
Neutropenia D009503 15 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Neurodermatitis D009450 1 associated lipids
Neuritis D009443 4 associated lipids
Nervous System Diseases D009422 37 associated lipids
Nerve Degeneration D009410 53 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Nephritis D009393 19 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Nail Diseases D009260 2 associated lipids
Myxedema D009230 2 associated lipids
Myelitis D009187 1 associated lipids
Mycoses D009181 18 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Mutism D009155 1 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Moyamoya Disease D009072 1 associated lipids
Mouth Diseases D009059 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Mite Infestations D008924 1 associated lipids
Metaplasia D008679 7 associated lipids
Meningoencephalitis D008590 4 associated lipids
Meningococcal Infections D008589 3 associated lipids
Memory Disorders D008569 33 associated lipids
Melanoma D008545 69 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Mediastinitis D008480 2 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Mastocytosis D008415 5 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Malacoplakia D008287 1 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Lymphoma D008223 18 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Lymphocele D008210 1 associated lipids
Lupus Nephritis D008181 8 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Abscess D008169 1 associated lipids
Long QT Syndrome D008133 10 associated lipids
Liver Diseases D008107 31 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Liver Abscess D008100 6 associated lipids
Listeriosis D008088 12 associated lipids
Lichen Planus D008010 3 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Leukoplakia D007971 1 associated lipids
Leukocytosis D007964 9 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Leukemia P388 D007941 43 associated lipids
Leukemia D007938 74 associated lipids
Lentigo D007911 1 associated lipids
Legionellosis D007876 3 associated lipids
Leg Injuries D007869 2 associated lipids
Labyrinthitis D007762 2 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Kidney Diseases D007674 29 associated lipids
Keloid D007627 12 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Ischemia D007511 18 associated lipids
Intussusception D007443 1 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Intestinal Fistula D007412 1 associated lipids
Intestinal Atresia D007409 3 associated lipids
Intertrigo D007402 1 associated lipids
Insulin Resistance D007333 99 associated lipids
Influenza, Human D007251 11 associated lipids
Inflammation D007249 119 associated lipids
Infection D007239 6 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Impetigo D007169 3 associated lipids
Immune System Diseases D007154 3 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Jorgensen WL Rusting of the lock and key model for protein-ligand binding. 1991 Science pmid:1719636
Kobayashi N et al. Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. 1991 Transplant. Proc. pmid:1703707
Keenan RJ et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. 1991 Transplantation pmid:1719668
Strasser S et al. The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. 1991 Transplant. Proc. pmid:1703709
Pichard L et al. Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. 1991 Transplant. Proc. pmid:1721279
Andersson J et al. The effects of FK 506 on cytokine production are dependent on the mode of cell activation. 1991 Transplant. Proc. pmid:1721311
Uemoto S et al. Experience with FK 506 in living related donor liver transplantation. 1991 Transplant. Proc. pmid:1721342
Tzakis AG et al. FK 506 versus cyclosporine in pediatric liver transplantation. 1991 Transplant. Proc. pmid:1721343
Morris SM et al. Disruption of renal function and gene expression by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721375
Lagodziński Z et al. Effect of FK 506 on B-cell responses. 1991 Transplant. Proc. pmid:1703359
Pirsch JD et al. Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. 1991 Transplant. Proc. pmid:1721406
Ito T et al. Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. 1991 Transplant. Proc. pmid:1721437
DeValeria PA et al. FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model. 1991 Transplant. Proc. pmid:1721438
Hohlfeld R [Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]. 1991 Nervenarzt pmid:1709725
Kay JE et al. Inhibition of T and B lymphocyte proliferation by rapamycin. 1991 Immunology pmid:1709916
Starzl TE et al. [Clinical experience with FK 506]. 1991 Presse Med pmid:1722311
Calne RY Immunosuppression for organ grafting. 1991 Transplant. Proc. pmid:1714646
Gailliot FP et al. Fluidized bed adsorption for whole broth extraction. 1990 Sep-Oct Biotechnol. Prog. pmid:1366874
Naouri A and Tissot E [Indications for liver transplantation in adults]. 1990 Jun-Jul J Chir (Paris) pmid:1698800
MacLeod AM and Thomson AW [FK-506. A new immunosuppressive drug]. 1990 Jul-Sep Medicina (Firenze) pmid:1706817
Wasik M et al. Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. 1990 Jul-Aug Immunopharmacology pmid:1699911
Thomson AW Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. 1990 Transplant. Proc. pmid:1689883
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Li PK et al. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. 1990 Adverse Drug React Acute Poisoning Rev pmid:1703724
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
McCauley J et al. The effects of FK 506 on renal function after liver transplantation. 1990 Transplant. Proc. pmid:1689887
Kang Y et al. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. 1990 Transplant. Proc. pmid:1689889
McCauley J et al. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. 1990 Lancet pmid:1690326
Hoffman AL et al. The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. 1990 Transplantation pmid:1690469
Woo J et al. The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. 1990 Scand. J. Immunol. pmid:1690915
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Morimoto T et al. Pancreaticoduodenal allotransplantation with FK 506 in the dog. 1990 Transplant. Proc. pmid:1691550
Yasunami Y et al. Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. 1990 Transplant. Proc. pmid:1691557
Iga C et al. Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. 1990 Transplant. Proc. pmid:1697118
Deguchi K et al. [Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]. 1990 No To Shinkei pmid:1697182
Murase N et al. Prevention of spontaneous diabetes in BB rats with FK 506. 1990 Lancet pmid:1697397
Justice RM et al. The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. 1990 Biochem. Biophys. Res. Commun. pmid:1697463
Todo S et al. Liver, kidney, and thoracic organ transplantation under FK 506. 1990 Ann. Surg. pmid:1697743
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia. 1990 Life Sci. pmid:1698241
Kurasawa K et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. 1990 Clin. Immunol. Immunopathol. pmid:1698584
Arita C et al. Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. 1990 Clin. Exp. Immunol. pmid:1702374
Woo J et al. Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. 1990 Clin. Exp. Immunol. pmid:1702375
Mattila PS et al. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. 1990 EMBO J. pmid:1702384
Kawashima H et al. Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. 1990 Invest. Ophthalmol. Vis. Sci. pmid:1702408
Wilkinson PC and Watson EA FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. 1990 Immunology pmid:1702750
Metcalfe S and Milner J Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. 1990 Immunol. Lett. pmid:1702753
Takada K et al. Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. 1990 J. Chromatogr. pmid:1703552
Woo J et al. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. 1990 Immunology pmid:1703987